What MicroPort CardioFlow does

MicroPort CardioFlow is a Shanghai-based medical device company specializing in interventional therapies for structural heart disease, with a product portfolio anchored by transcatheter aortic valve implantation (TAVI) systems, a left atrial appendage occluder, and a cardiac rhythm management (CRM) franchise following its December 2025 merger with MicroPort CRM. The company's core TAVI platform spans three generations: VitaFlow, VitaFlow Liberty, and VitaFlow Liberty Flex, the latter launched in December 2024. AnchorMan is its left atrial appendage occluder, and the post-merger CRM business adds pacemakers, defibrillators, and the SmartView remote monitoring ecosystem. The company is a majority-owned subsidiary of MicroPort Scientific Corporation and has been listed on the Hong Kong Stock Exchange (02160.HK) since its February 2021 IPO. The technology stack relies on self-expanding valve frames, delivery catheter engineering, and post-procedural remote monitoring rather than AI/ML as a core differentiator.

The business model is a per-procedure medical device sale to hospitals, with revenue recognized on implant. Products are sold directly through the company's own sales force in China and through a mix of direct and distributor channels internationally, with CE MDR and NMPA certifications supporting sales across approximately 40 countries and 900+ core hospitals. Approximately 20,000 patients have been treated cumulatively, and the company is targeting profitability in 2025 after narrowing its H1 2024 net loss by 67.8% year-over-year on standalone revenue of RMB 362M (USD ~50M) in FY2024 with a 70.9% gross margin. International expansion is the principal growth lever, with overseas implant volumes growing approximately 350% year-over-year across new market entries in Italy, Romania, Ecuador, Saudi Arabia, and others. The December 2025 MicroPort CRM merger, valued at approximately USD 680M, added a segment contributing roughly 20% of combined revenue, effectively converting the company from a single-indication structural heart specialist into a diversified structural heart plus CRM platform.

Name

MicroPort CardioFlow

Legal name

微创心通医疗科技有限公司

Website

https://cardioflowmedtech.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

MicroPort CardioFlow is a Shanghai-based medical device company developing transcatheter aortic valve implantation (TAVI) systems, left atrial appendage occluders, and post-merger cardiac rhythm management products for hospitals in approximately 40 countries, with a growing international franchise.

Ownership category

akta.pro rank

Product category

Structural Heart Disease and Cardiac Rhythm Management Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)

akta.pro secondary industries

Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts) (HLAHAFAH), Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI), Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)

Keywords

• Transcatheter aortic valve implantation
• Structural heart disease devices
• Cardiac rhythm management
• Left atrial appendage closure
• Interventional cardiology devices

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. TAVI Products and Accessories: Sale of transcatheter aortic valve implantation (TAVI) products including VitaFlow Liberty and related accessories (balloon expansion catheters, guidewires, sheath sets). One-time device sale per procedure.
2. Left Atrial Appendage Occluder (AnchorMan): Sale of AnchorMan left atrial appendage occluder system and its introduction system for stroke prevention in non-valvular atrial fibrillation patients. One-time device sale per procedure.
3. Cardiac Rhythm Management Products (Post-merger): Post-merger with MicroPort CRM, revenue from pacemakers, ICDs, CRT devices, and Holter diagnostic solutions. CRM segment contributed approximately 20% of combined group revenue in 2025.
4. Connected Cardiac Device Ecosystem: SmartView connected cardiac device ecosystem generating data-driven monitoring services. Revenue from IoT-enabled cardiac device solutions enabling remote patient monitoring and clinical decision-making.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

MicroPort CardioFlow designs, manufactures, and commercializes minimally invasive interventional medical devices for structural heart disease and cardiac rhythm management, including transcatheter aortic valve implantation (TAVI) systems (VitaFlow, VitaFlow Liberty, VitaFlow Liberty Flex), left atrial appendage occluders (AnchorMan), transcatheter mitral valve replacement (TMVR) systems, balloon dilation catheters (Alwide Plus, AccuSniper), guidewires (Angelguide), and post-merger cardiac rhythm management devices such as pacemakers, ICDs, and LBBAP delivery systems. The company sells these proprietary, self-developed products directly to hospitals and cardiac centers in China and through international channel partners across approximately 40 countries.

Product overview

MicroPort CardioFlow (微创心通) offers a comprehensive portfolio of structural heart disease and cardiac rhythm management products. The core TAVI portfolio spans three generations: VitaFlow (first-generation self-expanding bovine pericardial valve with electric delivery system), VitaFlow Liberty (second-generation globally unique electric recoverable TAVI system with dual-layer PET skirt and hybrid-density stent), and VitaFlow Liberty Flex (third-generation with 3D controlled-bending delivery system, the only truly coaxial controlled-bend self-expanding TAV system). Supporting TAVI procedures, the company provides Alwide Plus and AccuSniper balloon dilation catheters, Angelguide guide wire, and AnchorMan left atrial appendage closure system (China's only approved semi-closed LAAC device). Following the 2025 merger with MicroPort CRM, the company expanded into cardiac rhythm management with pacemakers (ENO, ALIZEA series), ICDs (TILEN/EYLEN, PLATINIUM), LBBAP delivery systems (FLEXIGO 3D), LBBOT ECG solution, and TMVR systems. The company also holds an interest in 4C Medical's AltaValve TMVR system. This integrated platform covers structural heart disease treatment, cardiac rhythm management, and heart failure management.

Differentiator

Problem solved

Functional benefit

Brands

• VitaFlow: First-generation transcatheter aortic valve implantation (TAVI) system - China's first domestically-made bovine pericardial valve
• VitaFlow Liberty
• VitaFlow Liberty Flex
• AnchorMan
• Alwide
• SmartView

Products and services

• VitaFlow Transcatheter Aortic Valve System (VitaFlow经导管主动脉瓣膜系统) First-generation self-expanding transcatheter aortic valve system using hybrid-density nitinol stent, bovine pericardial leaflets, and electric delivery system with large-mesh design reserving space for coronary intervention. Indicated for severe aortic stenosis patients unsuitable for surgical aortic valve replacement.
• VitaFlow Liberty Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty经导管主动脉瓣膜及可回收输送系统) Second-generation TAVI system featuring the world's only electric retrievable delivery system, hybrid-density self-expanding stent, bovine pericardial leaflets, and dual-layer PET skirt design. Delivers up to 3 retrieval opportunities with 360-degree bending of the valve segment. NMPA and CE MDR certified.
• VitaFlow Liberty Flex Transcatheter Aortic Valve Retrievable Controllable-Bend Delivery System (VitaFlow Liberty Flex经导管主动脉瓣可回收可控弯输送系统) Third-generation TAVI delivery system featuring the world's only true coaxial controllable-bend self-expanding TAV delivery with X3 Flexis 3D steering for smoother and safer aortic arch crossing and valve crossing. Includes Capsule in-tube bending technology, joint alignment function, and intelligent limit switch design. NMPA approved December 2024.
• Alwide Plus Cardiac Valve Balloon Dilation Catheter (Alwide Plus心脏瓣膜球囊扩张导管) Second-generation balloon dilation catheter with ultra-low compliance for precise balloon dilation, high burst pressure to expand severely calcified lesions, rapid inflation/deflation to minimize pacing time, and significantly improved puncture resistance for enhanced intraoperative balloon dilation safety. TAVI accessory.
• AccuSniper Double-Layer Balloon Dilation Catheter (AccuSniper双层球囊扩张导管) Third-generation double-layer balloon dilation catheter with special high-polymer materials, compliance inner-liner balloon, and non-compliance outer-balloon design. Anti-puncture performance improved 118% versus similar products, with '8'-shaped structure effectively locking the valve annulus.
• Angelguide Tip-Pre-Shaped Ultra-Stiff Guidewire (Angelguide尖端预塑形超硬导丝) Tip-pre-shaped ultra-stiff guidewire with high guidewire trajectory support and smooth transition characteristics, reducing possibility of vascular injury and improving release precision. TAVI accessory.
• AnchorMan Left Atrial Appendage Closure System (AnchorMan左心耳封堵器系统) China's only NMPA and CE MDR dual-certified left atrial appendage occluder. Features 12 '3D-folded' tail units forming a semi-closed structure with the frame, combining advantages of both open and closed occluders. Rounded soft distal end reduces tissue damage; nitinol mesh frame adapts to the left atrial appendage. Available in 6 occluder diameter sizes from 20mm to 35mm with push and retract release modes. Indicated for stroke prevention in non-valvular atrial fibrillation patients.
• Transcatheter Mitral Valve Replacement System (TMVR System) (经导管二尖瓣置换系统) Self-developed transcatheter mitral valve replacement system using apical or transseptal access routes for treating severe mitral regurgitation patients. Surgical device implantation time approximately 10-20 minutes, with immediate postoperative elimination of mitral regurgitation, no paravalvular leakage, and no LVOT obstruction. Indicated for high-surgical-risk mitral regurgitation patients.
• AltaValve Transcatheter Mitral Valve Replacement System (AltaValve经导管二尖瓣置换系统, via 4C Medical) World's only full-recapture transseptal low-profile transcatheter mitral valve replacement system, with a unique supra-annular valve and atrium-fixed design. Expected to become the world's first mitral regurgitation treatment requiring only atrium fixation, maximizing avoidance of LVOT obstruction risk. Has received two FDA Breakthrough Device Designations.
• ENO Series Implantable Cardiac Pacemaker (ENO系列植入式心脏起搏器) World's smallest transvenous cardiac pacemaker at only 8 cubic centimeters, with up to 12-year longevity, MRI compatibility, and AutoMRI smart MRI adaptation technology that automatically identifies magnetic fields and switches working modes. Includes sleep apnea monitoring function to expand clinical monitoring value. LBBAP indication approved in EU April 2026.
• ALIZEA Series Implantable Cardiac Pacemaker (ALIZEA系列植入式心脏起搏器) World's first CE-certified hybrid pacing system that maintains MRI conditional safety when used with other brand electrode leads. Integrates Bluetooth communication technology, supports SmartTouch tablet programmer wireless communication and SmartView Connect remote monitoring. Alizea, Borea, and Celea series with LBBAP indication.
• TILEN/EYLEN Implantable Cardioverter Defibrillator (TILEN/EYLEN植入式心律转复除颤器, ICD) New-generation implantable cardioverter defibrillator with Bluetooth connectivity and MRI conditional safety. AutoMRI function enables automatic device mode switching during MRI scans. Supports remote follow-up. Industry-leading battery longevity. China-launched ICD with Bluetooth connectivity.
• PLATINIUM Implantable Cardioverter Defibrillator (PLATINIUM植入式心律转复除颤器, ICD) China's first approved domestic ICD product with PARAD+ arrhythmia discrimination algorithm providing the lowest inappropriate shock rate among comparable products. AUTOMRI function supports automatic MRI mode switching for MRI compatibility.
• FLEXIGO 3D Left Bundle Branch Area Pacing (LBBAP) Delivery System (FLEXIGO 3D左束支起搏输送系统) Left bundle branch area pacing (LBBAP) delivery system with eight specifications of delivery sheaths and dedicated cutter. Features controllable navigation and precise positioning design. Eight optional catheter sheaths and dedicated cutter adapt to different patient anatomy and electrode lead specifications.
• LBBOT Innovative Solution (Smart ECG + Hookup Smart + RC115) (LBBOT创新解决方案) Portable real-time ECG device comprising Smart ECG device, Hookup Smart software, and RC115 connection cable. Supports Bluetooth connectivity, continuously displays 12-lead ECG, and automatically measures V6 lead RWPT and V6-V1 lead intervals. Used to optimize left bundle branch area pacing (LBBAP) surgical decision-making. Indicated for cardiac electrophysiology labs, operating rooms, and clinics.
• Evermend Cardiac Occluder Series (Evermend心脏封堵器系列) Congenital heart disease occluder series including atrial septal defect (ASD) occluder, ventricular septal defect (VSD) occluder, and patent ductus arteriosus (PDA) occluder and delivery system. Indicated for interventional treatment of congenital heart disease.

Quantifiable outcome

• VitaFlow clinical trials: 99.1% immediate device success rate; 1-year all-cause mortality 2.7%; 9-year all-cause mortality 45.3% with excellent valve durability
• +3 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core and moderate.

• Orange BusinesscoreTechnology or Integration · 24 June 2026Orange Business provides digital infrastructure, IoT platform, connectivity, and cybersecurity services for MicroPort CardioFlow's SmartView ecosystem, enabling patient data from implanted cardiac devices to be securely transmitted to healthcare professionals for remote monitoring and clinical decision-making. The partnership was extended for 5 years in June 2026. The connected medical device market is projected to grow from USD 87 billion to USD 173 billion by 2031.
• MicroPort CRM (MicroPort Cardiac Rhythm Management)coreStrategic or Co-development Partner · 21 December 2025MicroPort CardioFlow completed strategic merger with MicroPort CRM for USD 680 million in December 2025. CRM brings over 60 years of experience, 12 product lines, and 40+ globally marketed products (pacemakers, ICDs, CRT devices, Holter diagnostics). The combined entity aims to build a leading 'structural heart + cardiac rhythm + heart failure' integrated platform covering full cardiovascular disease spectrum.
• 4C Medical TechnologiesmoderateTechnology or Integration · 5 November 2021MicroPort CardioFlow invested in and became the largest shareholder of 4C Medical Technologies, a US-based company developing the AltaValve TMVR system — the world's first atrium-fixed TMVR solution. MicroPort CardioFlow holds exclusive commercial rights for AltaValve in China, Hong Kong, Macau, and Taiwan, and also obtained exclusive rights for 4C Medical's tricuspid valve product in China. 4C Medical raised USD 175 million in Series D (led by Boston Scientific, 2025).

Scale indicators11 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Edwards Lifesciences: Global leader in transcatheter heart valves with the Sapien TAVI platform, dominating the structural heart disease market. Directly competes with MicroPort CardioFlow's VitaFlow systems in international markets and represents the benchmark for TAVI technology, clinical evidence, and commercial scale.
• Venus MedTech: Chinese structural heart disease medical device company developing transcatheter heart valve products including TAVI and TMVR systems. Direct competitor in the Chinese TAVI market with overlapping product categories, similar regulatory pathways, and comparable target hospital accounts.
• Peijia Medical: Chinese structural heart and neurovascular interventional medical device company with TAVI products. Direct competitor in China's structural heart market, sharing the same target hospital accounts and competing for procedural volume with similar regulatory pathways (NMPA approved).

Broad incumbents

• Medtronic: Diversified medical device giant with the Evolut TAVI platform competing directly in structural heart, plus broad cardiac rhythm management and heart failure portfolios. Competes with MicroPort CardioFlow across multiple product categories post-CRM merger and represents a major incumbent threat globally.
• Boston Scientific: Major medical device company with structural heart (ACURATE neo TAVI platform) and cardiac rhythm management portfolios. Competes with MicroPort CardioFlow in both TAVI (after acquiring Symetis and Bolt Medical) and CRM segments. Boston Scientific also led 4C Medical's $175M Series D, making it a strategic investor in MicroPort CardioFlow's TMVR partner.
• Abbott Laboratories: Global medical device leader with structural heart (Tendyne TMVR, Portico TAVI) and cardiac rhythm management portfolios. Competes with MicroPort CardioFlow in TAVI markets and represents a critical competitor in the TMVR space where MicroPort CardioFlow is investing heavily via AltaValve (4C Medical).
• Shockwave Medical: Medical device company specializing in intravascular lithotripsy for calcium modification, increasingly relevant to TAVI procedure preparation. Now part of Johnson & Johnson. Adjacent competitor in the structural heart interventional space, addressing the same calcified patient anatomy that MicroPort CardioFlow targets.

Emerging players

• JenaValve Technology: Emerging structural heart company developing transcatheter aortic and tricuspid valve replacement systems with CE Mark for aortic regurgitation. Comparable to MicroPort CardioFlow as a focused, smaller player targeting specific structural heart indications with novel delivery technologies.
• 4C Medical Technologies: US-based developer of the AltaValve TMVR system, in which MicroPort CardioFlow is the largest shareholder with exclusive China commercialization rights. Atlas pivotal trial underway; FDA Breakthrough Device Designation received 2024. Closely tied to MicroPort CardioFlow as both portfolio asset and strategic investment.

Regional players

• Biosensors International: Asia-Pacific focused interventional cardiology company with structural heart and drug-eluting stent portfolios. Comparable as a regional structural heart player with international (especially Asian) market presence, overlapping target customers in cardiac catheterization labs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MicroPort CardioFlow